Assessment of Significant Pathway Signaling and Prognostic Value of GNG11 in Ovarian Serous Cystadenocarcinoma

References

• Torre LA, Islami F, Siegel RL, Ward EM, Jemal A. Global cancer in women: burden and trends. Cancer Epidemiol Biomarkers Prev. 2017;26(4):444–457. doi:10.1158/1055-9965.EPI-16-0858
   PubMed Web of Science ®Google Scholar
• Li J, Fadare O, Xiang L, Kong B, Zheng W. Ovarian serous carcinoma: recent concepts on its origin and carcinogenesis. J Hematol Oncol. 2012;5(1):8. doi:10.1186/1756-8722-5-8
   PubMed Web of Science ®Google Scholar
• Slomovitz B, Gourley C, Carey MS, et al. Low-grade serous ovarian cancer: state of the science. Gynecol Oncol. 2020;156(3):715–725. doi:10.1016/j.ygyno.2019.12.033
   PubMed Web of Science ®Google Scholar
• Fransson A, Glaessgen D, Alfredsson J, Wiman KG, Bajalica-Lagercrantz S, Mohell N. Strong synergy with APR-246 and DNA-damaging drugs in primary cancer cells from patients with TP53 mutant high-grade serous ovarian cancer. J Ovarian Res. 2016;9(1):27. doi:10.1186/s13048-016-0239-6
   PubMed Web of Science ®Google Scholar
• Vang R, Levine DA, Soslow RA, Zaloudek C, Shih Ie M, Kurman RJ. Molecular alterations of TP53 are a defining feature of ovarian high-grade serous carcinoma: a rereview of cases lacking TP53 mutations in the Cancer Genome Atlas Ovarian Study. Int J Gynecol Pathol. 2016;35(1):48–55. doi:10.1097/PGP.0000000000000207
   PubMed Web of Science ®Google Scholar
• Shapira I, Oswald M, Lovecchio J, et al. Circulating biomarkers for detection of ovarian cancer and predicting cancer outcomes. Br J Cancer. 2014;110(4):976–983. doi:10.1038/bjc.2013.795
   PubMed Web of Science ®Google Scholar
• Bachmayr-Heyda A, Aust S, Auer K, et al. Integrative systemic and local metabolomics with impact on survival in high-grade serous ovarian cancer. Clin Cancer Res. 2017;23(8):2081–2092. doi:10.1158/1078-0432.CCR-16-1647
   PubMed Web of Science ®Google Scholar
• Allemani C, Weir HK, Carreira H, et al. Global surveillance of cancer survival 1995–2009: analysis of individual data for 25,676,887 patients from 279 population-based registries in 67 countries (CONCORD-2). Lancet. 2015;385(9972):977–1010. doi:10.1016/S0140-6736(14)62038-9
   PubMed Web of Science ®Google Scholar
• Wu M, Sun Y, Wu J, Liu G. Identification of hub genes in high-grade serous ovarian cancer using weighted gene co-expression network analysis. Med Sci Monit. 2020;26:e922107.
   PubMed Web of Science ®Google Scholar
• Hua P, Zhang Y, Jin C, Zhang G, Wang B. Integration of gene profile to explore the hub genes of lung adenocarcinoma: a Quasi-Experimental Study. Medicine (Baltimore). 2020;99(43):e22727. doi:10.1097/MD.0000000000022727
   PubMed Web of Science ®Google Scholar
• Ruiz-Ballesteros E, Mollejo M, Rodriguez A, et al. Splenic marginal zone lymphoma: proposal of new diagnostic and prognostic markers identified after tissue and cDNA microarray analysis. Blood. 2005;106(5):1831–1838. doi:10.1182/blood-2004-10-3898
   PubMed Web of Science ®Google Scholar
• Hossain MN, Sakemura R, Fujii M, Ayusawa D. G-protein gamma subunit GNG11 strongly regulates cellular senescence. Biochem Biophys Res Commun. 2006;351(3):645–650. doi:10.1016/j.bbrc.2006.10.112
   PubMed Web of Science ®Google Scholar
• Takauji Y, Kudo I, En A, et al. GNG11 (G-protein subunit gamma 11) suppresses cell growth with induction of reactive oxygen species and abnormal nuclear morphology in human SUSM-1 cells. Biochem Cell Biol. 2017;95(4):517–523. doi:10.1139/bcb-2016-0248
   PubMed Web of Science ®Google Scholar
• Xing S, Wang Y, Hu K, Wang F, Sun T, Li Q. WGCNA reveals key gene modules regulated by the combined treatment of colon cancer with PHY906 and CPT11. Biosci Rep. 2020;40.
   Web of Science ®Google Scholar
• Mehrpour Layeghi S, Arabpour M, Esmaeili R, Naghizadeh MM, Tavakkoly Bazzaz J, Shakoori A. Evaluation of the potential role of long non-coding RNA LINC00961 in luminal breast cancer: a case-control and systems biology study. Cancer Cell Int. 2020;20(1):478. doi:10.1186/s12935-020-01569-1
   PubMed Web of Science ®Google Scholar
• Zheng MJ, Li X, Hu YX, et al. Identification of molecular marker associated with ovarian cancer prognosis using bioinformatics analysis and experiments. J Cell Physiol. 2019;234(7):11023–11036. doi:10.1002/jcp.27926
   PubMed Web of Science ®Google Scholar
• Cress RD, Chen YS, Morris CR, Petersen M, Leiserowitz GS. Characteristics of long-term survivors of epithelial ovarian cancer. Obstet Gynecol. 2015;126(3):491–497. doi:10.1097/AOG.0000000000000981
   PubMed Web of Science ®Google Scholar
• Kaern J, Aghmesheh M, Nesland JM, et al. Prognostic factors in ovarian carcinoma stage III patients. Can biomarkers improve the prediction of short- and long-term survivors? Int J Gynecol Cancer. 2005;15(6):1014–1022. doi:10.1111/j.1525-1438.2005.00185.x
   PubMed Web of Science ®Google Scholar
• Petrillo M, Fagotti A, Ferrandina G, et al. Ovarian cancer patients with localized relapse: clinical outcome and prognostic factors. Gynecol Oncol. 2013;131(1):36–41. doi:10.1016/j.ygyno.2013.06.020
   PubMed Web of Science ®Google Scholar
• Siegel RL, Miller KD, Jemal A. Cancer statistics, 2019. CA Cancer J Clin. 2019;69(1):7–34. doi:10.3322/caac.21551
   PubMed Web of Science ®Google Scholar
• Shi K, Li N, Yang M, Li W. Identification of key genes and pathways in female lung cancer patients who never smoked by a bioinformatics analysis. J Cancer. 2019;10(1):51–60. doi:10.7150/jca.26908
   PubMed Web of Science ®Google Scholar
• Zhang X, Kang X, Jin L, et al. ABCC9, NKAPL, and TMEM132C are potential diagnostic and prognostic markers in triple-negative breast cancer. Cell Biol Int. 2020;44(10):2002–2010. doi:10.1002/cbin.11406
   PubMed Web of Science ®Google Scholar
• Liu J, Li S, Lin L, et al. Co-expression network analysis identified atypical chemokine receptor 1 (ACKR1) association with lymph node metastasis and prognosis in cervical cancer. Cancer Biomark. 2020;27(2):213–223. doi:10.3233/CBM-190533
   PubMed Web of Science ®Google Scholar
• Yuan J, Xie A, Cao Q, Li X, Chen J, Fang Y. INHBB is a novel prognostic biomarker associated with cancer-promoting pathways in colorectal cancer. Biomed Res Int. 2020;2020:6909672. doi:10.1155/2020/6909672
   PubMed Web of Science ®Google Scholar
• Zhang HJ, Tao J, Sheng L, et al. Twist2 promotes kidney cancer cell proliferation and invasion by regulating ITGA6 and CD44 expression in the ECM-receptor interaction pathway. Onco Targets Ther. 2016;9:1801–1812. doi:10.2147/OTT.S96535
   PubMed Web of Science ®Google Scholar
• Peng W, Li JD, Zeng JJ, et al. Clinical value and potential mechanisms of COL8A1 upregulation in breast cancer: a comprehensive analysis. Cancer Cell Int. 2020;20(1):392. doi:10.1186/s12935-020-01465-8
   PubMed Web of Science ®Google Scholar
• Wang J, Zhang H, Zhou X, et al. Five serum-based miRNAs were identified as potential diagnostic biomarkers in gastric cardia adenocarcinoma. Cancer Biomark. 2018;23(2):193–203. doi:10.3233/CBM-181258
   PubMed Web of Science ®Google Scholar